狼疮肾炎无创生物标志物的研究进展

doi:10.3877/cma.j.issn.2095-655X.2023.04.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (445 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要狼疮肾炎(LN) 是系统性红斑狼疮(SLE)主要的并发症，是造成SLE患者死亡的重要原因。新型的无创生物标志物对LN的动态诊断和活动度监测具有重要意义。笔者主要对来源于血液及尿液的蛋白质类、细胞因子类及细胞外囊泡相关微小RNA等无创生物标志物进行综述，以期为LN的诊断、疾病活动度监测及预后判断提供参考思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：红斑狼疮, 系统性, 狼疮肾炎, 生物标志物, 诊断, 细胞外囊泡

Abstract：Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) that frequently leads to mortality for SLE patients. New noninvasive biomarkers play a crucial role in the dynamic diagnosis and activity monitoring of LN. In order to provide valuable insights for the diagnosis, disease activity monitoring, and prognosis evaluation of LN, this review evaluates noninvasive biomarkers, including proteins, cytokines, and extracellular vesicle-associated miRNAs from blood and urine.

Key words： Lupus erythematosus systemic Lupus nephritis Biomarkers Diagnosis Extracellular vesicles

收稿日期: 2022-12-30

基金资助:国家自然科学基金 (82172346)

通讯作者: 李珉珉， Email：limm269@126.com

引用本文:

郭芳芳李珉珉. 狼疮肾炎无创生物标志物的研究进展[J]. 中华诊断学电子杂志, 2023, 11(4): 271-275.
Guo Fangfang, Li Minmin. Research progress on non-invasive biomarkers of lupus nephritis. zhzdx, 2023, 11(4): 271-275.

链接本文:

http://www.zhzdxzz.com/CN/10.3877/cma.j.issn.2095-655X.2023.04.011 或 http://www.zhzdxzz.com/CN/Y2023/V11/I4/271

［1］Anders HJ,Saxena R,Zhao MH,et al.Lupus nephritis［J］.Nat Rev Dis Primers,2020,6(1):7.DOI:10.1038/s41572-019-0141-9. ［2］中国狼疮肾炎诊断和治疗指南编写组.中国狼疮肾炎诊断和治疗指南［J］.中华医学杂志,2019,99(44):3441-3455.DOI:10.3760/cma.j.issn.0376-2491.2019.44.001. ［3］Obri瘙塂c B,Jurubi瘙塅 R,Andronesi A,et al.Histological predictors of renal outcome in lupus nephritis:the importance of tubulointerstitial lesions and scoring of glomerular lesions［J］.Lupus,2018,27(9):1455-1463.DOI:10.1177/0961203318776109. ［4］Singh JA,Hossain A,Kotb A,et al.Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis:a systematic review and network meta-analysis［J］.Syst Rev,2016,5(1):155.DOI:10.1186/s13643-016-0328-z. ［5］Stanley S,Vanarsa K,Soliman S,et al.Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities［J］.Nat Commun,2020,11(1):2197.DOI:10.1038/s41467-020-15986-3. ［6］Birmingham DJ,Merchant M,Waikar SS,et al.Biomarkers of lupus nephritis histology and flare:deciphering the relevant amidst the noise［J］.Nephrol Dial Transplant,2017,32(suppl_1):i71-i79.DOI:10.1093/ndt/gfw300. ［7］Parodis I,Tamirou F,Houssiau FA.Treat-to-target in lupus nephritis.What is the role of the repeat kidney biopsy?［J］.Arch Immunol Ther Exp (Warsz),2022,70(1):1-8.DOI：10.1007/s00005-022-00646-9. ［8］Hull KL,Adenwalla SF,Topham P,et al.Indications and considerations for kidney biopsy:an overview of clinical considerations for the non-specialist［J］.Clin Med (Lond),2022,22(1):34-40.DOI:10.7861/clinmed.2021-0472. ［9］Ferragut F,Vachetta VS,Troncoso MF,et al.ALCAM/CD166:a pleiotropic mediator of cell adhesion,stemness and cancer progression［J］.Cytokine Growth Factor Rev,2021（61）:27-37.DOI:10.1016/j.cytogfr.2021.07.001. ［10］Stanley S,Vanarsa K,Soliman S,et al.Author correction:comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities［J］.Nat Commun,2020,11(1):3131.DOI:10.1038/s41467-020-16944-9. ［11］Lei R,Vu B,Kourentzi K,et al.A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM［J］.Front Immunol,2022(13):1044743.DOI:10.3389/fimmu.2022.1044743. ［12］Chalmers SA,Ayilam Ramachandran R,Garcia SJ,et al.The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses［J］.J Clin Invest,2022,132(1).DOI:10.1172/JCI147334. ［13］Ding H,Lin C,Cai J,et al.Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology［J］.Arthritis Res Ther,2020,22(1):122.DOI:10.1186/s13075-020-02209-9. ［14］Mller HJ.Soluble CD163［J］.Scand J Clin Lab Invest,2012,72(1):1-13.DOI:10.3109/00365513.2011.626868. ［15］ Li J, Yu YF, Liu CH, et al. Significance of M2 macrophages in glomerulonephritis with crescents［J］.Pathol Res Pract,2017,213(9):1215-1220.DOI:10.1016/j.prp.2017.04.011. ［16］Huang YJ,Lin CH,Yang HY,et al.Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis［J］.Front Immunol,2022(13):935700.DOI:10.3389/fimmu.2022.935700. ［17］Zhang T,Li H,Vanarsa K,et al.Association of urine sCD163 with proliferative lupus nephritis,fibrinoid necrosis,cellular crescents and intrarenal M2 macrophages［J］.Front Immunol,2020(11):671.DOI:10.3389/fimmu.2020.00671. ［18］Mejia-Vilet JM,Zhang XL,Cruz C,et al.Urinary soluble CD163:a novel noninvasive biomarker of activity for lupus nephritis［J］.J Am Soc Nephrol,2020,31(6):1335-1347.DOI:10.1681/ASN.2019121285. ［19］Parodis I,Gokaraju S,Zickert A,et al.ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus［J］.Rheumatology (Oxford),2020,59(9):2237-2249.DOI:10.1093/rheumatology/kez528. ［20］Yap D,Kwan L,Ma M,et al.Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis:a cohort study［J］.Nephrol Dial Transplant,2019,34(3):467-473.DOI:10.1093/ndt/gfy024. ［21］Yu KY,Yung S,Chau MK,et al.Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis［J］.Lupus,2021,30(7):1039-1050.DOI:10.1177/09612033211004727. ［22］Fasano S,Pierro L,Borgia A,et al.Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus:an exploratory study［J］.Rheumatology (Oxford),2020,59(11):3193-3200.DOI:10.1093/rheumatology/keaa074. ［23］Liu L,Wang R,Ding H,et al.The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients［J］.PLoS One,2020,15(10):e0240942.DOI:10.1371/journal.pone.0240942. ［24］Nagai K,Matsubara T,Mima A,et al.Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy［J］.Kidney Int,2005,68(2):552-561.DOI:10.1111/j.1523-1755.2005.00433.x. ［25］Mok CC,Ding HH,Kharboutli M,et al.Axl,ferritin,insulin-like growth factor binding protein 2,and tumor necrosis factor receptor type II as biomarkers in systemic lupus erythematosus［J］.Arthritis Care Res (Hoboken),2016,68(9):1303-1309.DOI:10.1002/acr.22835. ［26］Gong S, Xu Z, Liu Y, et al. Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis［J］.Eur J Clin Invest,2019,49(3):e13064.DOI:10.1111/eci.13064. ［27］Parodis I,Ding H,Zickert A,et al.Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis［J］.PLoS One,2019,14(2):e0212068.DOI:10.1371/journal.pone.0212068. ［28］Farah Izati A,Wong KK,Che Maraina CH.IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis［J］.Malays J Pathol,2020,42(3):333-347. ［29］Haroon MM, Hegazy GA, Hassanien MA, et al. Significance of interleukin 23 in systemic lupus patients:relation to disease activity and damage indices［J］.Biologics,2023(17):1-9.DOI:10.2147/Btt.S389021. ［30］Dedong H,Feiyan Z,Jie S,et al.Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients［J］.Immunol Lett,2019(210):33-39.DOI:10.1016/j.imlet.2019.04.002. ［31］Talaat RM,Mohamed SF,Bassyouni IH,et al.Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients:correlation with disease activity［J］.Cytokine,2015,72(2):146-153.DOI:10.1016/j.cyto.2014.12.027. ［32］Karasu E,Eisenhardt SU,Harant J,et al.Extracellular vesicles:packages sent with complement［J］.Front Immunol,2018(9):721.DOI:10.3389/fimmu.2018.00721. ［33］Zhao Y,Wei W,Liu ML.Extracellular vesicles and lupus nephritis-new insights into pathophysiology and clinical implications［J］.J Autoimmun,2020(115):102540.DOI:10.1016/j.jaut.2020.102540. ［34］Hinger SA,Cha DJ,Franklin JL,et al.Diverse long RNAs are differentially sorted into extracellular vesicles secreted by colorectal cancer cells［J］.Cell Rep,2018,25(3):715-725.e4.DOI:10.1016/j.celrep.2018.09.054. ［35］Solé C,Cortés-Hernández J,Felip ML,et al.miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis［J］.Nephrol Dial Transplant,2015,30(9):1488-1496.DOI:10.1093/ndt/gfv128. ［36］Tangtanatakul P,Klinchanhom S,Sodsai P,et al.Down-regulation of let-7a and miR-21 in urine exosomes from lupus nephritis patients during disease flare［J］.Asian Pac J Allergy Immunol,2019,37(4):189-197.DOI:10.12932/AP-130318-0280. ［37］Garcia-Vives E, Solé C, Moliné T, et al. The urinary exosomal miRNA expression profile is predictive of clinical response in lupus nephritis［J］.Int J Mol Sci,2020,21(4):1372.DOI:10.3390/ijms21041372. ［38］Li Y,Xu X,Tang X,et al.MicroRNA expression profile of urinary exosomes in Type IV lupus nephritis complicated by cellular crescent［J］.J Biol Res (Thessalon),2018(25):16.DOI:10.1186/s40709-018-0088-0. ［39］Zheng C,Xie L,Qin H,et al.The role of extracellular vesicles in systemic lupus erythematosus［J］.Front Cell Dev Biol,2022(10):835566.DOI:10.3389/fcell.2022.835566.